Pharmacokinetics of Cetriaxon in bone

Institut for Pharmacology and Toxicology0 个研究点目标入组 40 人开始时间: 2006年12月15日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•We will include patients (women and men) from 40 to 65 years which are, for clinical reasons, undergoing a hip replacement therapy in the participating centre. The patients must be able to understand and sign informed consent that the patient is willing to participate in the study.
•Women must be postmenopausal.
•We will use only patients with no relevant and accompanying diseases like:
•prior traumatic surgery
•past or present osteomyelitis
•impaired function of the heart ( > NYHA II)
•impaired function of the kidney (creatinine > 1,5 mg/ml)
•impaired function of the liver (high GOT-value)
•high body mass index (BMI > 35)
•allergy against cephalosporine
•allergy against ß-lactame-antibiotics
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients who are unable to consent will not be included in the study.
•Based on the literature, cephalosporine can be used in pregnancy. For safety reasons premenopausal women will be excluded from this trial.
•We will exclude patients with relevant and accompanying diseases like:
•prior traumatic surgery
•past or present osteomyelitis
•impaired function of the heart ( > NYHA II)
•impaired function of the kidney (creatinine > 1,5 mg/ml)
•impaired function of the liver (high GOT-value)
•high body mass index (BMI > 35)
•allergy against cephalosporine
•allergy against ß-lactame-antibiotics

发起方

Institut for Pharmacology and Toxicology